Lactate-Mediated H3K18la-KIF20A-c-Myc-PD-L1 Axis: A Druggable Pathway for Immune Resistance in Hepatocellular Carcinoma

Study Background and Research Question

Hepatocellular carcinoma (HCC) remains a major global health burden, with high mortality and limited response rates to current immunotherapies. Although immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have provided modest improvements, most patients still experience resistance, often linked to the immunosuppressive tumor microenvironment (TME). Metabolic reprogramming, particularly enhanced glycolysis and consequent lactate accumulation, is increasingly recognized as a driver of immune evasion. However, the precise epigenetic mechanisms connecting these metabolic changes to immunotherapy resistance have not been fully elucidated. The reference study (Cancer Biol Med 2026) addresses this gap by investigating how lactate influences chromatin modifications and downstream pathways involved in immune escape in HCC.

Key Innovation from the Reference Study

The central innovation of this study is the identification of a novel, pharmaceutically reversible metabolic-epigenetic pathway: lactate-driven histone H3 lysine 18 lactylation (H3K18la) directly activates transcription of KIF20A, which then stabilizes c-Myc and upregulates PD-L1 expression. This axis—H3K18la–KIF20A–c-Myc–PD-L1—links glycolytic metabolism to immune resistance and provides a targetable mechanism for restoring immunotherapy sensitivity in HCC. The study is among the first to mechanistically connect lactate-induced histone modification with the regulation of immune checkpoint molecules and to demonstrate that glycolysis inhibition can reverse this epigenetic immune resistance pathway.

Methods and Experimental Design Insights

The authors conducted a multi-modal investigation using both clinical samples and experimental models:

• Clinical Correlations: Immunohistochemistry (IHC) was performed on 89 paired HCC and adjacent tissues to quantify H3K18la and assess correlation with tumor stage. A separate cohort of 46 HCC patients was analyzed for the association between H3K18la levels and anti-PD-1 therapy resistance.
• Target Identification: Chromatin immunoprecipitation sequencing (ChIP-seq) in HCC cell lines was used to identify KIF20A as a direct transcriptional target of H3K18la.
• Mechanistic Validation: Dual-luciferase reporter assays and ChIP-PCR confirmed direct regulation of KIF20A by H3K18la and its downstream effects on c-Myc and PD-L1.
• Functional Immune Assays: HCC cells (with genetic knockdown or overexpression of key pathway components) were co-cultured with CD8⁺ T cells to assess T cell activation and cytotoxicity via flow cytometry.
• In Vivo Evaluation: A subcutaneous mouse xenograft model was used to test the impact of glycolysis inhibition (using a glycolysis inhibitor) in combination with anti-PD-1 therapy on tumor growth and immune microenvironment.

Core Findings and Why They Matter

The study's main discoveries advance our understanding of immune resistance in HCC on several fronts:

• H3K18 Lactylation as a Biomarker: Tumor samples with high H3K18la levels were strongly correlated with advanced stage and therapy resistance, suggesting this epigenetic mark could serve as a prognostic biomarker.
• Lactate-Driven Epigenetic Activation: Accumulation of lactate in the TME enhanced H3K18la, which directly activated KIF20A transcription. This step establishes a mechanistic bridge between tumor metabolism and gene regulation.
• KIF20A–c-Myc–PD-L1 Axis: Upregulated KIF20A stabilized c-Myc protein, leading to increased PD-L1 expression. Elevated PD-L1 suppresses CD8⁺ T cell function and facilitates immune escape. This provides a precise molecular route for glycolysis-induced immune evasion.
• Therapeutic Reversibility: Genetic silencing of KIF20A, or pharmacological inhibition of glycolysis, restored T cell cytotoxicity and reduced tumor immune resistance. Notably, the combination of a glycolysis inhibitor with anti-PD-1 therapy synergistically inhibited tumor growth and improved survival in vivo (Cancer Biol Med 2026).

These results highlight a druggable axis—where metabolic interventions can reprogram the epigenetic state of tumors to boost immunotherapy efficacy. This supports the emerging paradigm that targeting metabolic-epigenetic crosstalk is critical for overcoming resistance in solid tumors.

Comparison with Existing Internal Articles

Several recent resources have emphasized the translational importance of glycolysis inhibition in cancer research. For example, the article "2-Deoxy-D-glucose (2-DG) for Reliable Glycolysis Inhibition" outlines how 2-DG, a validated glycolytic inhibitor, enables sensitive and reproducible modulation of cellular metabolism in cancer models. Similarly, "Strategic Glycolysis Inhibition: Advancing Translational Oncology" discusses how metabolic oxidative stress inducers such as 2-DG have been leveraged to sensitize tumors to immunotherapies and reprogram immune cell fate.

The current HCC study provides mechanistic depth to these translational workflows by revealing how inhibiting glycolytic flux can dismantle an epigenetic resistance pathway, rather than simply reducing ATP supply. This molecular detail aligns with guidance in "2-Deoxy-D-glucose: A Precision Glycolysis Inhibitor for Cancer Research", which advocates for integrating metabolic and immunological endpoints in experimental design. By mechanistically linking glycolysis inhibition with reversal of immune checkpoint upregulation, the reference study offers a robust scientific rationale for synergistic combination therapies targeting both metabolism and immune evasion mechanisms.

Limitations and Transferability

While the findings provide compelling evidence for the H3K18la–KIF20A–c-Myc–PD-L1 axis as a therapeutic target, several limitations should be considered:

• Model Systems: The in vivo validation was performed in subcutaneous xenograft models, which may not fully recapitulate the complexity of human HCC or its immune microenvironment.
• Clinical Translation: The pharmacological inhibitor used in preclinical models may have different pharmacokinetics or off-target effects in humans compared to animal studies.
• Epigenetic Complexity: Although the study focuses on H3K18la, other lactate-induced modifications and epigenetic marks could also play roles in immune regulation and require further investigation.
• Generalizability: While the axis was demonstrated in HCC, its relevance to other tumor types—such as KIT-positive gastrointestinal stromal tumors or non-small cell lung cancer—remains to be systematically explored in future studies.

Protocol Parameters

• Glycolysis inhibition in HCC models: In the reference study, glycolysis inhibitors were administered in vivo in combination with anti-PD-1 therapy; dosing and timing were optimized for murine xenograft models. Researchers should titrate concentrations in vitro (e.g., 5–10 mM for 24 hours), in line with established protocols.
• Assessment of immune function: Co-culture HCC cells (with or without pathway modulation) with CD8⁺ T cells, followed by flow cytometry for cytotoxicity and activation markers.
• Detection of histone lactylation: Employ immunohistochemistry or ChIP-based assays to quantify H3K18la in tumor tissues or cell lines, correlating with clinical or experimental endpoints.

Research Support Resources

To enable reproducible glycolysis inhibition and mechanistic interrogation of metabolic-epigenetic pathways, researchers may utilize 2-Deoxy-D-glucose (2-DG, SKU B1027), a competitive glucose analog validated across cancer and immunometabolic models. According to product information and benchmarked workflows, 2-DG is effective as a metabolic oxidative stress inducer and supports investigation of glycolysis-linked immune resistance in solid tumors. APExBIO offers technical specifications and guidance for experimental use. By integrating tools like 2-DG into study designs, investigators can further dissect and target the metabolic drivers of immune evasion highlighted in the recent HCC research.